Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Topiramate + amitriptyline is a combination of two small molecule drugs used primarily for the prevention of migraine headaches, especially in patients with comorbid depression. Topiramate is an antiepileptic drug that acts as a carbonic anhydrase inhibitor and modulates voltage-gated sodium channels, enhances GABAergic activity, antagonizes AMPA/kainate glutamate receptors, and inhibits certain calcium channels. Amitriptyline is a tricyclic antidepressant that inhibits the reuptake of serotonin and norepinephrine and has anticholinergic effects. The combination may offer improved efficacy in migraine prophylaxis compared to monotherapy with either agent alone and can result in higher patient satisfaction with potentially fewer side effects due to lower required doses of each component[2]. However, this combination increases the risk of pharmacokinetic interactions (notably increased amitriptyline levels), which may raise the risk of adverse effects such as increased body temperature or decreased sweating[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on topiramate + amitriptyline.